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of this issue map out a novel genetic
strategy for systematically examining
the functional significance of DP
signature genes both in its own lineage
specification and, more broadly, in HF
morphogenesis. Future gene ablation
studies using DP-specific Cre lines will
undoubtedly reveal the molecular
identity of DP lineage master regu-
lators. An in-depth understanding of
the DP lineage commitment program
will help devise protocols for achieving
highly inductive patient-specific DP
cells and improve prospects for HF
bioengineering therapies for alopecia.
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Figure 1. Dermal papilla (DP) lineage program. DP cells form during embryonic HF development from initially uncommitted mesenchymal precursors. Formation
of the DP lineage likely follows a stereotypical cell lineage program, which starts with the commitment event. Although DP lineage commitment is likely
associated with stable gene expression changes, signaling characteristics of differentiated DP cells are unstable and can be rapidly lost in culture. Signaling
networks of DP lineage can now be studied using several stage-specific Cre lines. Mechanisms of the DP lineage commitment and differentiation can be exploited
for developing optimized HF bioengineering therapies for alopecia (listed at the top). iPS, induced pluripotent stem; Shh, Sonic hedgehog.
Psoriasis and Cardiovascular Disease:
Where Is the Risk?
Catriona M. Maybury1, Jonathan N. Barker1 and Catherine H. Smith1
In this issue, Dowlatshahi et al. publish results from their population-based study
in Rotterdam showing that, despite an increase in body mass index and smoking,
individuals with psoriasis have no increased risk of incident cardiovascular disease.
These results should be interpreted with caution: the study included relatively
small numbers of patients with psoriasis, most of whom had mild disease.
Journal of Investigative Dermatology (2013) 133, 2308–2311. doi:10.1038/jid.2013.207
Background to psoriasis and
cardiovascular risk
Psoriasis is now recognized as a chronic
inflammatory skin disease that is more
than ‘‘skin deep.’’ The reported associa-
tion between psoriasis and cardiovas-
cular disease (CVD) has attracted
considerable interest in the last decade
See related articles on pg 2340 and 2347
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since Mallbris et al. (2004) reported data
from a large cohort study comparing
CVD mortality in hospitalized patients
with psoriasis, outpatients with psori-
asis, and the general population. They
observed no increased mortality for
outpatients with psoriasis, but they did
identify a significantly increased risk of
death from CVD for patients with psori-
asis requiring hospital admission. In
2006, the first population-based study
indicating that psoriasis may confer
an independent risk of myocardial
infarction (MI) was published in the
journal JAMA (Gelfand et al., 2006).
Subsequent studies showed that psori-
asis is also a risk factor for stroke and
thromboembolism. A recent systematic
review and meta-analysis of 17 studies
reporting the incidence (as opposed to
the prevalence) of CVD events in indivi-
duals with psoriasis indicates that CVD
risk predominates in individuals who
have severe disease, with marked increa-
ses in the incidence of MI, stroke, and
all-cause CVD mortality (Samarasekera
et al., 2013). The relative risks appear to
be greatest in younger individuals,
although the absolute number of CVD
events attributable to psoriasis per year
remains modest and especially low for
young individuals and for those with
mild disease. The review also highlights
the difficulties in interpreting these data:
descriptors of disease severity rely largely
on surrogate markers such as healthcare
use (for example hospitalization or use of
systemic therapy), and inter-study hetero-
geneity exists for all CVD outcomes.
Discrepancies are likely to reflect impor-
tant differences in study design, how the
diagnosis and disease severity of psori-
asis was ascertained, and whether the
patients were drawn from a primary or
secondary care setting. Although, on
balance, the literature supports an associ-
ation between psoriasis and CVD,
Wakkee et al. (2010) concluded that
psoriasis may not be an independent
risk factor for CVD as indicated by rates
of hospitalization due to ischemic heart
disease in people with psoriasis com-
pared to those without. Notably, this
study was also based in Rotterdam, and
the majority of participants had mild
disease.
Cardiovascular disease and psoriasis:
proposed pathogenesis
Although an association between psor-
iasis and CVD is, with a few exceptions,
reported consistently, it is less certain
that the relationship is causal. It is
important to state that all possible
mechanisms are theoretical. In the
1960s, Framingham epidemiologists
identified hypertension, smoking, dia-
betes, and hyperlipidemia as coronary
risk factors (Ridker et al., 2007). These
‘‘traditional’’ risk factors are more
common in individuals with psoriasis
and could account for some, if not all, of
the increased risk of CVD in this group.
More recently, the metabolic syndrome
has entered medical terminology to
describe the clustering of insulin resis-
tance or diabetes, abdominal obesity,
hypertension, and hyperlipidemia, and
it is strongly associated with CVD. In a
large population-based study, Langan
et al. showed an increased prevalence
of metabolic syndrome in individuals
with psoriasis in the UK. This associa-
tion was ‘‘dose dependent’’ and increa-
sed with disease severity (Langan et al.,
2011).
Inflammation has been hypothesized
as an independent CVD risk factor
(recognized through the addition of
high-sensitivity C-reactive protein to
more recent cardiovascular risk scoring)
(Ridker et al., 2007). The burden of
chronic inflammation in psoriasis may
confer a degree of risk that is indepen-
dent of traditional coronary risk factors
or in a manner that may exacerbate their
impact. In particular, overproduction of
Th-1 cytokines in psoriasis (such as
TNF-a, IFN-g) may disturb endothelial
function (Pietrzak et al., 2013). In an
animal study using mice with psoriasi-
form dermatitis (KC-Tie2 mice) and an
absence of comorbidities, aortic root
inflammation was present in 33% of
the affected KC-Tie2 group compared
with 0% in the controls (P¼ 0.04). Bio-
markers of CVD risk, including C-reac-
tive protein and TNF-a, were also
elevated in the KC-Tie2 group. After
treatment of skin inflammation, the
aortic root lesions resolved. These data
suggest that at least in murine models
skin inflammation alone promotes vas-
cular inflammation and thrombosis
(Wang et al., 2012). Again, not all data
are consistent with this hypothesis:
Martyn-Simmons et al. (2011), for exam-
ple, detected no difference in endothe-
lial dysfunction in a cross-sectional
cohort of patients with severe psoriasis
without traditional CVD risk and
controls.
Areas of uncertainty
Therefore, although significant progress
in knowledge regarding CVD risk in
patients with psoriasis has been made,
fundamental questions remain, including
the following: What are the pathogenic
mechanisms for the development of
CVD in this group? How important is
psoriasis-associated inflammation as a
risk factor for CVD? Does treatment of
psoriasis attenuate CVD risk?
Clinical Implications (from the Rotterdam
Study)
 Patients with mild psoriasis, managed in the community, can be reassured
that the absolute risk of developing cardiovascular disease (CVD) is not
significantly different compared with the rest of the general population.
However, they may still have an increased risk of developing traditional
CVD risk factors such as hyperlipidemia.
 Dermatologists treating patients with moderate-to-severe psoriasis should
remain vigilant in detecting and managing CVD and should refer to their
relevant guidelines for the management of CVD, such as the recently
published UK NICE Psoriasis guidelines (http://publications.nice.org.uk/
psoriasis-cg153).
 The pathogenic mechanisms linking psoriasis and CVD remain uncertain,
requiring further research.
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‘‘Psoriasis and cardiovascular events: the
Rotterdam Study,’’ Dowlatshahi et al.
In this issue of the Journal, Dowlatshahi
et al. (2013) report results from a pros-
pective population-based study aimed
to assess the risk of subclinical athero-
sclerosis, coronary heart disease, stroke,
and heart failure in patients with psori-
asis. This was performed as part of the
larger ‘Rotterdam Study’ (http://www.
epib.nl/research/ergo.htm), using data
from individuals over 55 years living in
one Dutch suburb. Cases were identi-
fied via a search of general practitioner
records for a physician diagnosis of
psoriasis or evidence of medication for
psoriasis. The reference population was
subjects with no medical or drug history
related to psoriasis. The medical records
of all participants were assessed conti-
nuously over a decade for significant
events. The primary outcome was inci-
dent cardiovascular disease (morbidity
and mortality). Secondary outcomes
were components of CVD (MI, stroke,
heart failure) and subclinical measures
of atherosclerosis.
Data were collected for 262 patients
with psoriasis and 8,009 reference
subjects. The mean age of the patients
was 64 years; 44% were men. Psoriasis
area severity index (PASI) scores were
available for 14% of patients and ranged
from 0.4 to 12.7. The majority of
patients (75%) had mild disease (defined
as a PASI o10 or using no therapy or
topical therapy alone). Psoriasis patients
smoked more, had an increased body
mass index, and used more lipid-low-
ering medication than reference sub-
jects. There were no significant differ-
ences in the incidence of CVD, MI,
stroke, and heart failure between those
with psoriasis and the control group.
There were no significant differences
in carotid intima-media thickness or
coronary artery calcification (subclinical
markers of atherosclerosis) between the
groups. Seventy-two percent of psoriasis
patients were identified to have a
carotid plaque compared with 65% of
the reference population (P¼0.09).
Strengths and weaknesses of study
This was a prospective population-
based study, drawn from a commu-
nity setting, avoiding the significant
ascertainment bias of many previous
hospital-based case–control studies.
Earlier population studies using health
records data formulated their evidence
on information obtained via interna-
tional disease classification (ICD) or
Oxford Medical Information System
(OXMIS) coding, which could introduce
misclassification bias. Therefore, this
study is unique in assessing individuals
across the whole spectrum of disease, in
the community setting and not in a
healthcare setting, and by the fact that
the psoriasis diagnosis was made either
by a doctor or through a validated
algorithm, with follow-up taking place
over a 10-year period. Furthermore, be-
cause the aim was to investigate CVD,
the Rotterdam group gathered compre-
hensive data on cardiovascular risk
factors that other databases failed to
capture: the study looked at both surro-
gate markers of CVD health and hard
CVD end points with correction for
confounders.
The main drawback is the small
number of participants with psoriasis
(259) and the low number of cardiovas-
cular events in the psoriasis group dur-
ing the study period (28). Individuals
were categorized as having moderate-
to-severe psoriasis if they were using
either phototherapy or a systemic drug.
This was a minority of patients (63
patients or 24% of the psoriasis cohort).
Rotterdam participants were predomi-
nantly in late middle age, an age group
in which other studies indicate that the
relative risks of MI are lower. Previous
population-based studies demonstrating
a positive association between psoriasis
and CVD included much larger num-
bers of individuals with psoriasis of all
severities. For example, in the study by
Gelfand et al. (2006), the number of
patients with severe disease (based on
those receiving systemic therapy) was
3,837. Therefore, the Rotterdam Study
may have been underpowered to detect
a difference between the groups. A
power calculation was not made at the
outset to determine adequate sample
size, and this introduces the risk of a
type-11 error (the effect is interpreted
as not significant when the association
does exist).
Disease severity scoring (PASI) data
were only available in 14% of the
patients; therefore, attribution of disease
severity was, in common with most
other studies, judged by medication
use. Participants were classified as hav-
ing either mild (no or topical therapy)
or moderate-to-severe psoriasis (using
either phototherapy or systemic therapy).
Supplementary Figure 2: Incidence
estimates for MI in people with psoriasis
compared to people without stratified
by age—(A) mild psoriasis; (B) severe
psoriasis (Samarasekera et al., 2013).
Conclusion
The Rotterdam Study supports existing
data that individuals with mild psoriasis
do not have an increased risk of deve-
loping CVD. However, the majority
of published literature suggests that
there is an increased risk of developing
CVD in individuals with severe psoria-
sis. The low numbers of individuals with
severe disease in this study means that
their results are not powerful enough to
negate such prior evidence.
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Mechanisms of Contact Sensitization
Offer Insights into the Role of Barrier
Defects vs. Intrinsic Immune
Abnormalities as Drivers of Atopic
Dermatitis
Nikhil Dhingra1,2, Nicholas Gulati1 and Emma Guttman-Yassky1,3
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by wet,
oozing, erythematous, pruritic lesions in the acute stage and xerotic, lichenified
plaques in the chronic stage. It frequently coexists with asthma and allergic rhinitis,
sharing some mechanistic features with these diseases as part of the ‘‘atopic march.’’
Controversy exists as to whether immune abnormalities, epidermal barrier defects,
or both are the primary factors responsible for disease pathogenesis. In AD patients,
there is often a coexisting irritant contact dermatitis (ICD) or allergic contact
dermatitis (ACD) that is sometimes clinically difficult to distinguish from AD. ACD
shares molecular mechanisms with AD, including increased cellular infiltrates and
cytokine activation (Gittler et al., 2013). In this issue, Newell et al. (2013) used an
experimental contact sensitization model with dinitrochlorobenzene (DNCB) to gain
insight into the unique immune phenotype of AD patients.
Journal of Investigative Dermatology (2013) 133, 2311–2314. doi:10.1038/jid.2013.239
Epidermal barrier defects characterize
lesional and nonlesional AD skin
The stratum corneum, including terminal
differentiation proteins such as filaggrin
(FLG), corneodesmosin, and loricrin, is a
first-line defense against irritants and
allergens. The genomic expression of
key barrier molecules, which comprise
the epidermal differentiation complex on
chromosome 1q21, have been pre-
viously shown to be downregulated in
AD patients in both lesional and nonle-
sional skin (Sua´rez-Farin˜as et al., 2011).
Furthermore, frequent mutations in the
FLG gene (found in up to 30–50% of AD
patients) have been associated with the
severity of AD (as identified by the
Scoring of AD (SCORAD) index). These
differentiation abnormalities contribute
to the barrier defect in AD, ultimately
resulting in increased transepidermal
water loss, xerosis, and greater penetra-
tion of various agents (Gittler et al.,
2013). In humans, FLG deficiency has
been linked to increased risk of the other
atopic diseases, as well as to greater
See related article on pg 2372
susceptibility to common triggers of AD
(including allergens and microbes).
Murine models with reduced FLG ex-
hibit greater passive transfer of protein
allergens and reduced thresholds to irri-
tants (Irvine et al., 2011). These studies
provide the basis for the ‘‘outside-in’’
hypothesis of AD, which states that
transfer of external triggers across a dys-
functional barrier elicits the disease’s
characteristic immune responses.
Although FLG and other defects in the
barrier have been linked to AD
pathogenesis, there are notable limita-
tions to this hypothesis. For example, an
inverse correlation has been established
between the expression levels of several
terminal differentiation molecules and
AD disease severity (as measured by the
SCORAD index) (Sua´rez-Farin˜as et al.,
2011). This raises the possibility of a
reactive epidermal barrier to a primary
immune insult. Furthermore, impressive
reductions in key terminal differentia-
tion molecules, extending far beyond
FLG, have been found even in non-
lesional AD skin. In addition, a
majority of AD patients do not harbor
FLG mutations, and even those with
them have been shown to outgrow the
disease (Guttman-Yassky et al., 2011).
Collectively, these observations suggest
that barrier dysfunction is not the sole
contributor to disease pathogenesis.
AD is primarily Th2 and Th22 polarized
The historical immune paradigm for
AD characterized it largely as a
T helper type 2 (Th2)-mediated disease
with high levels of IL-4, IL-13, and
Th2-polarizing chemokines (i.e.,
CCL17, CCL18, and CCL22). Recent
work has implicated additional key
Th2-associated cytokines and factors,
including IL-31, thymic stromal lympho-
poietin (TSLP), and OX40. Th2 signaling
has been demonstrated to produce
many of the molecular findings seen in
AD skin, with the exception of the
characteristic epidermal hyperplasia.
Allergen-specific Th2 T cells can be
found in AD but not in nonatopic con-
trols (Ardern-Jones et al., 2007). More
recently, Th22 T cells and their
cytokine, IL-22, have been shown to
have a key role in the pathogenesis of
AD, potentially accounting for the incre-
ased epidermal thickness. Langerhans
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